Parkman Healthcare Partners LLC Buys 66,503 Shares of Qiagen (NYSE:QGEN)

Parkman Healthcare Partners LLC lifted its holdings in shares of Qiagen (NYSE:QGEN - Free Report) by 31.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 277,272 shares of the company's stock after purchasing an additional 66,503 shares during the quarter. Qiagen accounts for about 1.6% of Parkman Healthcare Partners LLC's portfolio, making the stock its 22nd biggest position. Parkman Healthcare Partners LLC owned about 0.12% of Qiagen worth $12,347,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Park Avenue Securities LLC boosted its stake in shares of Qiagen by 32.1% during the fourth quarter. Park Avenue Securities LLC now owns 8,908 shares of the company's stock valued at $397,000 after purchasing an additional 2,166 shares in the last quarter. Wells Fargo & Company MN increased its position in Qiagen by 31.8% in the 4th quarter. Wells Fargo & Company MN now owns 66,779 shares of the company's stock valued at $2,974,000 after buying an additional 16,106 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Qiagen by 34.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 16,409 shares of the company's stock valued at $731,000 after purchasing an additional 4,225 shares during the period. LPL Financial LLC lifted its position in Qiagen by 2.6% in the 4th quarter. LPL Financial LLC now owns 17,240 shares of the company's stock valued at $768,000 after acquiring an additional 432 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its position in Qiagen by 83.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,565 shares of the company's stock valued at $70,000 after buying an additional 712 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on QGEN. Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. UBS Group cut their price target on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Robert W. Baird upped their target price on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. StockNews.com raised Qiagen from a "buy" rating to a "strong-buy" rating in a research report on Friday, May 9th. Finally, Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Seven research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Qiagen has an average rating of "Hold" and a consensus target price of $48.42.

Qiagen Trading Down 2.0%

Shares of QGEN opened at $42.08 on Wednesday. The firm has a 50-day moving average price of $40.80 and a 200 day moving average price of $41.78. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $9.35 billion, a P/E ratio of 117.17, a P/E/G ratio of 2.39 and a beta of 0.67. Qiagen has a 12-month low of $37.63 and a 12-month high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. The business had revenue of $483.46 million during the quarter, compared to analysts' expectations of $465.66 million. During the same quarter last year, the business posted $0.44 EPS. The business's quarterly revenue was up 5.2% compared to the same quarter last year. Sell-side analysts forecast that Qiagen will post 2.26 EPS for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.